Handbook of Contemporary Neuropharmacology

3 Volume Set

Sibley, David R. / Hanin, Israel / Kuhar, Michael / Skolnick, Phil (Herausgeber)

1. Auflage April 2007
2992 Seiten, Hardcover
Wiley & Sons Ltd

Kurzbeschreibung

Written at the professional level, the Handbook of Contemporary Neuropharmacology consists of chapters reviewing basic and advanced topics in neuropharmacology. The scope of the Handbook is heavily pre-clinical, covering mostly basic science topics; however, the chapters are organized under a clinical 'umbrella'.

An online version of the Handbook is available on Wiley InterScience.

ISBN: 978-0-471-66053-8

John Wiley & Sons

Probekapitel

Zum Shop

A comprehensive, accessible reference for neuropharmacology

Recognizing the central role of neuropharmacology in drug development, therapy, and the potential for developing novel classes of neuropharmacologic agents stemming from current research, prominent experts collaborated to develop this comprehensive, up-to-date reference that consolidates information about the latest approaches and advances in neuropharmacology in general, and in the research and treatment of specific conditions. Edited by leaders in neuropharmacology and featuring chapters by respected authorities in their specialty areas, Handbook of Contemporary Neuropharmacology is an invaluable resource for pharmacologists, neurologists, psychiatrists, pharmaceutical professionals, and students. It covers basic neuropharmacology and then delves into its applications in research and in treating specific disorders:
* Mood Disorders
* Anxiety and Stress Disorders
* Schizophrenia and Psychosis
* Substance Abuse and Addictive Disorders
* Pain
* Sleep and Arousal
* Development and Developmental Disorders
* Neurodegenerative and Seizure Disorders
* Neuroimmunology
* Eating and Metabolic Disorders

Preface.

Contributors.

VOLUME 1.

PART I: BASIC NEUROPHARMACOLOGY.

PART II: MOOD DISORDERS.

VOLUME 2.

PART I: ANXIETY AND STRESS DISORDERS.

PART II: SCHIZOPHRENIA AND PSYCHOSIS.

PART III: SUBSTANCE ABUSE AND ADDICTIVE DISORDERS.

PART IV: PAIN.

VOLUME 3.

PART I: SLEEP AND AROUSAL.

PART II: DEVELOPMENT AND DEVELOPMENTAL DISORDERS.

PART III: NEURODEGENERATIVE AND SEIZURE DISORDERS.

PART IV: NEUROIMMUNOLOGY.

PART V: EATING AND METABOLIC DISORDERS.

Cumulative Index.

DAVID R. SIBLEY, PhD, is a Senior Investigator and Chief of the Molecular Neuropharmacology Section in the National Institute of Neurological Disorders and Stroke, National Institutes of Health. His laboratory is currently investigating the molecular, cellular, and biochemical properties of dopamine receptors and their role in neuronal signaling and pathophysiological states.

ISRAEL HANIN, PhD, is Professor and Chair Emeritus in the Department of Pharmacology at Loyola University Chicago. He formerly worked at the National Institute of Mental Health, Laboratory of Preclinical Pharmacology, and at the University of Pittsburgh Department of Psychiatry. Dr. Hanin's research has focused on cholinergic mechanisms, animal models for Alzheimer's disease, and the potential role of glycosaminoglycans in the treatment of Alzheimer's disease.

MICHAEL KUHAR, PhD, is currently a Candler Professor and Georgia Research Alliance Professor of Neuropharmacology at the Yerkes Primate Center at Emory University. He previously was a professor in the Neuroscience Department at Johns Hopkins, and a branch chief at the National Institute on Drug Abuse. Dr. Kuhar has published more than 800 articles, abstracts, book chapters, reviews, and patents.

PHIL SKOLNICK, PhD, D.Sc. (hon.), is Executive Vice President and Chief Scientific Officer for DOV Pharmaceutical, Inc. He was formerly a Lilly Fellow in Neuroscience and also served as Chief of the Laboratory of Neuroscience, National Institutes of Health.

D. R. Sibley, National Institute Neurological Disorders, Bethesda, MD; I. Hanin, Loyola Univ. Chicago, Maywood, IL; M. Kuhar, Emory Univ., Atlanta, GA; P. Skolnick, DOV Pharmaceuticals, Somerset, NJ